Скачать презентацию
Идет загрузка презентации. Пожалуйста, подождите
Презентация была опубликована 10 лет назад пользователемИнна Вересаева
1 Инфраструктура инновационной деятельности в области биотехнологии в России Р.Г. ВАСИЛОВ Общество биотехнологов России им. Ю.А. Овчинникова
2 Международные сопоставления наукоемкости и наукоотдачи Доля расходов на исследо- вания и разработки (ИР) в ВВП Числен- ность ученых и инженеров, занятых в ИР (на 10 тыс. населения) Текущий индекс конкуренто- способнос- ти (место в мире) Доля высоко- технологич- ной продукции в товарном экспорте (%) Доля в мировом экспорте информати- зационного оборудо- вания (%) Произво- дитель- ность труда (тыс. долл. ВВП на одного занятого) США2, ,1 КИТАЙ15,544207,17,2 ЯПОНИЯ2, ,756 ИНДИЯ1,231,65660,074,9 ГЕРМАНИЯ2,4831,613184,856 РОССИЯ134,87080,0418
3 Крупнейшие секторы мировой экономики
4 99% of all biomedical Research occurs outside of Merck The Virtual Lab Concept All Merck scientists are charged with building a virtual lab by mounting the best scientific program in their area, whether it comes from internal research, external collaborations or both
5 Key Products: Licensed Products or Patents: 44% of total sales 2005 Revenues: $22 Billion FOSAMAX COZAAR / HYZAAR NEXIUM VARIVAX RECOMBIVAX HB Over $9.5 billion, or 44% of Mercks sales, are attributed to alliance products and patents Merck licensing strategy results in high-value alliances
6 Combining Internal Capabilities and External Innovation Mercks R&D strategy – Embracing partnerships Ensure a strong internal research capability Leverage this capability through collaborations Evaluate potential transactions –Open door! –From early- to late-stage product opportunities –Coordinated approach –Quick response back to potential partners about Mercks level of interest
7 Линейная инновационная модель Серийное производство Опытное производство Опытные и конструкторские работы Прикладные исследования Фундаментальные исследования Фундаментальные исследования
8 Нелинейная инновационная модель
10 Aя
11 Proof of Concept and Funding Gap Funding Gap Basic Research Public Funding Applied Research Proof of Concept Seed Funding Licensing Public Funding Private Funding Idea First data Development Preclinical Feasibility Funding Research & Development Stages
13 Technology Transfer Offices More then 500 TTO in Europe Most successful - Germany, Great Britain, Austria Russian Chain of TTO - 21 organizations (2005)
14 Technology Transfer Offices Functions of TTO: Monitoring of R&D process Monitoring of R&D process Monitoring of the market Monitoring of the market Good connections in the industry Good connections in the industry Intellectual Right Protection Intellectual Right Protection Efficiency estimations: Number of the licenses for production Number of the licenses for production Revenues under the licenses agreement Revenues under the licenses agreement
15 Results of work of the Russian Technology Transfer Chain in : proposals was revised proposals was revised preliminary negotiations for the projects preliminary negotiations for the projects - 11 license agreements for production - 11 license agreements for production
16 Best countries for outsourcing Forbes has chosen 7 countries to outsource from: India Philippines Russia China Canada Mexico Ireland Outsourcing is perfect for Russia Forbes Forbes
17 Growth areas for outsourcing: Pre-clinical studies Phase I studies Peri-approval studies Niche services International studies and services
18 Activity of CROs Target identification Lead Generation Toxicology facility Analytical laboratory Clinical pharmacology site Full-service CRO
19 Todays Status and Future possibilities for Russias CRO and BioTech companies TodayTomorrow IP not at doubt Joint work on IP-improvement with western Pharm Industry Good quality Certified Quality (ISO, GLP, GMP) Import Biology (proteins, cells, etc.) Export Biology (proteins, assays) Companies offer and have expertise in either Chemistry or Biology Fusion of Biology and Chemistry for real Drug Discovery Projects Looked upon as suppliers/vendors – NOT yet partners Looked upon as Critical Partners - NOT just suppliers R&D and manufacturing facilities in change State-of-the-art R&D & manufacturing facilities Government announced Bio Tech as priority growth sector Government will actively support with taxation and other incentives Russian scientist work abroad Russian scientist return home Russia imports drugs Russia produces drugs in Russia
20 ОБЩЕСТВО БИОТЕХНОЛОГОВ РОССИИ ИМ. Ю.А. ОВЧИННИКОВА г. Москва Тел.:
Еще похожие презентации в нашем архиве:
© 2024 MyShared Inc.
All rights reserved.